# A Double-blind Study to Investigate Efficacy, Safety and Tolerability of BAY1142524 in Patients With Type II Diabetes and a Clinical Diagnosis of Diabetic Kidney Disease

Study · id `cardio:ct-nct03412006` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT03412006](<https://clinicaltrials.gov/study/NCT03412006>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT03412006

Browse, organ or system: Kidneys; Metabolism  
Browse, condition area: Diabetes and metabolic disease; Kidney connections  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 152 participants.

## Technical summary

Registry record NCT03412006. Randomized; quadruple masking; primary purpose treatment. Start 2018-02-02 (actual); primary completion 2019-10-02 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 152 participants (enrolled count; ClinicalTrials.gov record NCT03412006, source copy `cardio:ctgov-nct03412006-2022-03-03`, retrieved 2026-10-26)
- Started: 2018-02-02 (actual) (ClinicalTrials.gov record NCT03412006, source copy `cardio:ctgov-nct03412006-2022-03-03`, retrieved 2026-10-26)
- Primary completion: 2019-10-02 (actual) (ClinicalTrials.gov record NCT03412006, source copy `cardio:ctgov-nct03412006-2022-03-03`, retrieved 2026-10-26)
- Completion: 2019-10-10 (actual) (ClinicalTrials.gov record NCT03412006, source copy `cardio:ctgov-nct03412006-2022-03-03`, retrieved 2026-10-26)
- Countries: Bulgaria; Denmark; Finland; Israel; Italy; Spain; Sweden (ClinicalTrials.gov record NCT03412006, source copy `cardio:ctgov-nct03412006-2022-03-03`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct03412006-2022-03-03`, retrieved 2026-10-26)

## The registry's words

- Brief title: A Double-blind Study to Investigate Efficacy, Safety and Tolerability of BAY1142524 in Patients With Type II Diabetes and a Clinical Diagnosis of Diabetic Kidney Disease
- Acronym: CADA DIA
- Condition: Diabetic Kidney Disease
- Intervention (Drug): Fulacimstat (BAY1142524)
- Intervention (Drug): Placebo
- Lead sponsor: Bayer
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Diabetic kidney disease (`cardio:diabetic-nephropathy`)
- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry condition terms include this condition: Diabetes mellitus (`core:diabetes-mellitus`)
- Registry lists this organization as the lead sponsor: Bayer (`cardio:bayer`)

## Provenance

Content hash: 209dd571ee1b3977ab0bf66c8a9cb6fef4966c197a458c8e47f64dfa48377a63
Last substantive edit: 2026-10-31
Evidence last checked: Not recorded
